Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thrombosis 3 Venous Thromboembolism 3 Neoplasms 3 Pancreatic Neoplasms 2 Venous Thormboembolism 1 Thrombosis 1 Thromboembolism 1 Stroke 1 Soft Tissue Neoplasms 1 Sarcoma 1 Pulmonary Embolism 1 Ovarian Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Catheter-Related Infections 1 Carcinoma, Pancreatic Ductal 1

Interventions

Paclitaxel 96 Carboplatin 81 Bevacizumab 62 Gemcitabine 36 liposomal doxorubicin 32 pembrolizumab 30 Topotecan 26 olaparib 23 Taxes 23 niraparib 17 Immunoglobulin G 17 Disulfides 17 Docetaxel 16 Cyclophosphamide 16 Cisplatin 14 Nivolumab 11 rucaparib 10 durvalumab 10 Doxorubicin 9 Albumin-Bound Paclitaxel 8 sargramostim 7 pazopanib 7 fludarabine phosphate 7 fludarabine 7 avelumab 7 Magnetic Resonance Spectroscopy 7 Ifosfamide 7 epacadostat 6 Trabectedin 6 Sorafenib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Ovarian Neoplasms × Enoxaparin × Clear all

NCT00908960 2017-12-19

MicroTEC

Dana-Farber Cancer Institute

Phase 2 Completed

70 enrolled 9 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡